TEJ-KOHLI-FOUNDATION
19.12.2019 14:11:12 CET | Business Wire | Press release
On the fourth anniversary of the Tej Kohli Cornea Institute in Hyderabad, the Tej Kohli Foundation has renewed its commitment of $14m of funding from 2020. During 2019 5,736 individuals were cured of blindness or severe visual impairment at The Tej Kohli Cornea Institute, which is a collaboration between the Tej Kohli Foundation in London, and the LV Prasad Eye Institute in Hyderabad, a World Health Organization Collaborating Centre.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005417/en/
The Tej Kohli Cornea Institute was inaugurated in December 2015 to tackle the problem of poverty blindness by providing free treatment to anyone who needs it. Since its inauguration the Cornea Institute has taken care of 223,404 outpatients, completed 43,255 surgical procedures, collected 38,225 donor corneas into its eye bank, utilized 22,176 donor corneas, trained 152 clinicians, published 202 papers and given 892 educational presentations.
Reaching people living with blindness and severe visual impairment in the hard-to-reach rural areas where 66% of Indians live is a particular challenge that the Tej Kohli Cornea Institute is uniquely solving. A unique presence of eye care centres in villages supplemented with a fully equipped mobile diagnostics van take eye care directly to hard-to-reach patients, with more than 100 corneal transplants completed so far in these rural areas.
Other 2019 operational highlights at the Tej Kohli Cornea Institute included:
- 280,000 individuals called the ‘Call Netra’ toll free eye care helpline.
- A special privilege ‘Keratoplasty card’ was issued to corneal transplant patients to ensure priority check-ups and access to care anytime and anywhere.
- An education app was launched to continually assess cornea doctors in their evaluations.
- The ECHO project linked expert specialist teams with clinicians in remote local communities.
According to the World Health Organisation, 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. 14m live in India, where between 6m and 7m people are currently waiting for a corneal transplant. At least 300,000 children in India have some form of severe visual impairment or blindness.
Whilst approximately 75% of corneal disease is curable, the costs of corneal transplantation surgery using donor cornea, and the many years of medicine needed to prevent rejection, makes treatment inaccessible to many. Born out of a partnership with the LV Prasad Eye Institute and the Tej Kohli Foundation, the Tej Kohli Cornea Institute is focussed on prevention, treatment and cure at no cost directly into these high-impact populations that are living needlessly with corneal blindness.
Dr Pravin K Vaddavalli, MD, Director of Tej Kohli Cornea Institute said:
“The last four years have been an opportunity to assess the magnitude of the problem of corneal blindness, create strategic partnerships to expand our reach and start to evolve ways and means to allow these patients to live longer, more productively and with dignity.”
Wendy Kohli, co-Founder of the Tej Kohli Foundation said:
“It’s an uncomfortable reality that millions of people worldwide are living with curable blindness that persists entirely because they cannot afford to access treatment. The impact of restoring a person’s vision on that person’s confidence, wellbeing and economic prospects is substantial. Through the Tej Kohli Cornea Institute we are able to make direct interventions into individual lives that help and transform entire families every single day.”
---
About The Tej Kohli Cornea Institute
The mission of the Tej Kohli Cornea Institute is to prevent, control and eliminate corneal blindness worldwide. The Institute is a global leader in research and development, preventative medicine, education and cornea transplants. The Institute enables access to affordable treatment through systemic long-term efforts to create widespread access to high-quality eye care facilities that are delivered by people with the resources, technical skills and compassion to handle diverse population segments.
http://www.tejkohlicorneainstitute.com
About LV Prasad Eye Institute
Established in 1987, the LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The Institute has ten active arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation and Product Development. LVPEI's mission is to provide equitable and quality eye care to all sections of society.
About the Tej Kohli Foundation
Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness worldwide. Since 2015 the Foundation has funded the provision of corneal transplants in underserved communities in India through the Tej Kohli Cornea Institute; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness. In December 2019 the Foundation launched the ‘Future Bionics’ program to gift 3D printed bionic arms to children and young people who are living with limb difference in the United Kingdom.
http://www.tejkohlifoundation.com
END
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005417/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
